MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
46.30
+0.01
+0.02%
Closed 19:59 12/31 EST
OPEN
46.14
PREV CLOSE
46.29
HIGH
46.48
LOW
45.07
VOLUME
1.75M
TURNOVER
0
52 WEEK HIGH
90.32
52 WEEK LOW
41.50
MARKET CAP
2.49B
P/E (TTM)
-25.1453
1D
5D
1M
3M
1Y
5Y
1D
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)
Barchart · 12/30/2025 19:00
Weekly Report: what happened at SLNO last week (1222-1226)?
Weekly Report · 12/29/2025 10:31
BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise
Reuters · 12/23/2025 12:25
Weekly Report: what happened at SLNO last week (1215-1219)?
Weekly Report · 12/22/2025 10:31
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
PR Newswire · 12/16/2025 17:21
Weekly Report: what happened at SLNO last week (1208-1212)?
Weekly Report · 12/15/2025 10:39
Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market Segments
TipRanks · 12/11/2025 19:35
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise
Benzinga · 12/11/2025 18:17
More
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.